# Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood.

> **NCT05338541** · PHASE1 · UNKNOWN · sponsor: **Yizhuo Zhang** · enrollment: 30 (estimated)

## Conditions studied

- Neuroblastoma in Children

## Interventions

- **DRUG:** Tucidinostat and etoposide

## Key facts

- **NCT ID:** NCT05338541
- **Lead sponsor:** Yizhuo Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-27
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05338541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05338541, "Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05338541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*